Alnylam Pharmaceuticals
ALNY
$147.89
Share price
-1.33%
Change (1 day)
-28.28%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Earnings for Alnylam Pharmaceuticals (ALNY)
Earnings in 2023 (TTM): -$0.32 B
According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are -$0.2 B. an increase over its 2022 earnings that were of -$0.98 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Alnylam Pharmaceuticals from 2003 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2023  | -$0.32 B | -67.84% |
| 2022 | -$0.98 B | 36.93% |
| 2021 | -$0.71 B | -8.04% |
| 2020 | -$0.78 B | -15.66% |
| 2019 | -$0.92 B | 12.23% |
| 2018 | -$0.82 B | 62.91% |
| 2017 | -$0.51 B | 17.78% |
| 2016 | -$0.43 B | 43.44% |
| 2015 | -$0.3 B | 60.69% |
| 2014 | -$0.19 B | 98.2% |
| 2013 | -$92.95 M | |
| 2011 | -$54.82 M | 27.48% |
| 2010 | -$43.01 M | -10.92% |
| 2009 | -$48.28 M | 95.77% |
| 2008 | -$24.66 M | |
| 2006 | -$39.51 M | -9.13% |
| 2005 | -$43.48 M | 34.74% |
| 2004 | -$32.27 M | 36.79% |
| 2003 | -$23.59 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $9.82 B | -5,082.68% | 🇨🇭 Switzerland |
 Sanofi SNY | $7.26 B | -3,781.52% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $4.04 B | -2,149.46% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $34.06 M | -117.27% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | -$29.44 M | -85.08% | 🇺🇸 USA |
 OPKO Health
OPK | -$0.19 B | -6.54% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $0.40 B | -305.35% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | -$0.29 B | 43.26% | 🇺🇸 USA |